Mirena Extension Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

364

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions
Contraception
Interventions
DRUG

Levonorgestrel IUS (Mirena, BAY86-5028)

Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.

Trial Locations (49)

10032

New York

11777

Port Jefferson

16507

Erie

19104

Philadelphia

19107

Philadelphia

21208

Pikesville

21702

Frederick

23114

Midlothian

23235

North Chesterfield

23456

Virginia Beach

27408

Greensboro

27713

Durham

28557

Morehead City

28562

New Bern

28602

Hickory

28801

Asheville

30342

Atlanta

37404

Chattanooga

44124

Mayfield Heights

46825

Fort Wayne

48604

Saginaw

68510

Lincoln

77030

Houston

78758

Austin

80045

Aurora

83404

Idaho Falls

85032

Phoenix

85251

Scottsdale

85712

Tucson

87109

Albuquerque

89106

Las Vegas

92024

Encinitas

93003

Ventura

94110

San Francisco

97239

Portland

98105

Seattle

98122

Seattle

36608-6703

Mobile

47630-8940

Newburgh

02118

Boston

03756-1000

Lebanon

08648

Lawrenceville

07753

Neptune City

27103-1749

Winston-Salem

45005-2593

Franklin

76104-4145

Fort Worth

84020-7163

Draper

24013-2256

Roanoke

99207-1240

Spokane

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY